2025 Annual General Meeting
Released
Released
Announcement PDF
2025 Annual General Meeting
15 September 2025 – Sydney, Australia: Recce Pharmaceuticals Ltd (ASX:RCE, FSE:R9Q)
(Recce or the Company), the company developing a new class of Synthetic Anti-Infectives,
advises that its Annual General Meeting is scheduled for Wednesday, 5 November 2025, further
details of which will be provided in the notice of meeting to be dispatched to shareholders in due
course.
In accordance with Listing Rule 3.13.1, Listing Rule 14.3, and Clause 14.3 of the Company’s
Constitution, the Company advises that the closing date for the receipt of director nominations is
Tuesday, 23 September 2025.
This announcement has been approved for release by Recce Pharmaceuticals Board.
About Recce Pharmaceuticals Ltd
Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) is developing a New Class of Synthetic Anti-Infectives
designed to address the urgent global health problems of antibiotic-resistant superbugs and emerging viral
pathogens.
Recce’s anti-infective pipeline includes three patented, broad-spectrum, synthetic polymer anti-infectives:
RECCE® 327 (R327) as an intravenous and topical therapy that is being developed for the treatment of
serious and potentially life-threatening infections due to Gram-positive and Gram-negative bacteria, including
their superbug forms; RECCE® 435 (R435) as an orally administered therapy for bacterial infections; and
RECCE® 529 (R529) for viral infections. Through their multi-layered mechanisms of action, Recce’s antiinfectives have the potential to overcome the processes utilised by bacteria and viruses to overcome
resistance – a current challenge facing existing antibiotics.
The World Health Organization (WHO) added R327, R435, and R529 to its list of antibacterial products in
clinical development for priority pathogens, recognising Recce’s efforts to combat antimicrobial resistance.
The FDA granted R327 Qualified Infectious Disease Product designation under the Generating Antibiotic
Initiatives Now (GAIN) Act, providing Fast Track Designation and 10 years of market exclusivity post
approval. R327 is also included on The Pew Charitable Trusts’ Global New Antibiotics in Development
Pipeline as the sole synthetic polymer and sepsis drug candidate in development.
Recce wholly owns its automated manufacturing, supporting current clinical trials. Recce’s anti-infective
pipeline aims to address synergistic, unmet medical needs by leveraging its unique technologies.
Share your feedback
Discover